Furthermore, combining high CEACAM1 with low EPHA2 and low CEACAM6 expression showed very significant correlations whether in advanced disease stages (Figure 4H, blue line) or throughout CRC development (Supplementary Figure 6H, blue line) as compared to patients expressing high CEACAM1/high CEACAM6/high EPHA2 (Figure 4H and Supplementary Figure 6H, purple lines) or those expressing low CEACAM1/ high CEACAM6/high EPHA2 (Figure 4H and Supplementary Figure 6H, brown lines). The gene discussed is CEACAM1; the disease is colorectal carcinoma.